PDF herunterladen
CC BY 4.0 · Journal of Diabetes and Endocrine Practice
DOI: 10.1055/s-0045-1804531
Original Article

Management of Ophthalmopathy and Use of Selenium in Graves' Disease: A Survey of Physicians from the Middle East and Africa

Salem A. Beshyah 
1   Department of Medicine, Dubai Medical College for Girls, Dubai, United Arab Emirates
,
Aly B. Khalil 
2   Department of Medicine, Bareen International Hospital (NMC-RH-MBZ), Abu Dhabi, United Arab Emirates.
3   Department of Endocrinology, Reem Hospital, Abu Dhabi, United Arab Emirates
,
Mohammed Bashir
4   Department of Medicine, Hamad Metabolic Institute, Hamad Medical Corporation, Doha, Qatar
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objectives We explored how physicians in the Middle East and Africa (MEA) assess and manage Graves' ophthalmopathy (GO) and ascertain their perceptions of selenium (Se) in thyroid disease.

Methods Two online questionnaires were sent to a sample of physicians from the MEA region. Responses from 183 GO and 102 Se surveys were received and analyzed.

Results In the GO survey, 68.6% thought multidisciplinary team (MDT) was very valuable, but fewer participated in MDT (19.0%) or referred patients to MDT (44.2%). Respondents advocated the assessment of visual fields by perimetry (65.9%), magnetic resonance imaging (52.9%), color vision (51.8%), and ultrasonography (14.1%). Autoimmune thyroid diseases (ATDs) were the most common choice (95.1%) for first-line therapy for coexisting hyperthyroidism. Glucocorticoids (GCs) were preferred as the first-line therapy by the majority of respondents; among them, 63.1% chose the intravenous route. The treatment strategy for GO with intravenous GC therapy remains debatable and surgical decompression (31.3%) and radiotherapy (13.1%) were recommended. When diabetes coexists, radiotherapy and orbital decompression are more favored over GCs. Regarding the Se survey, a minority (10.3%) used Se routinely for Graves' disease (GD). However, this increased to 29.1% when GO exists. However, about a quarter needed to be sure/did not know (23.9%) the evidence in GD without GO and 27.4% for GD with GO. In GD without GO on ATDs, 67.5% never recommend Se, whereas 32.5% recommend Se sometimes. Conversely, when GO occurs, 65.0% recommend Se in variable frequencies. Of these, Se is used as an alternative to watchful waiting in patients with mild ocular involvement (22.1%) and as an adjuvant to the established treatment in patients with moderate to severe ocular involvement (20.4%). The dose of 200 mcg/day was recommended by 42.5% of respondents.

Conclusion Gaps exist in the physicians' knowledge and practices concerning diagnosis and management of GO. More focused education and training are needed in the MEA region.

Keywords

clinical management - Graves' ophthalmopathy - Graves' disease - selenium - thyroid eye disease - thyrotoxicosis

Authors' Contributions

S.A.B. adapted the questionnaire and managed the online survey. All other authors reviewed the data and contributed to the data analysis and interpretation, drafting and revising of the manuscript, and approval of its final version.


Compliance with Ethical Principles

The study was approved by the Institutional Review Board of Sheikh Khalifa Medical City, Abu Dhabi. Respondents provided informed consent digitally before they could answer the survey questions and all data were analyzed anonymously.


Supplementary Material



Publikationsverlauf

Artikel online veröffentlicht:
09. April 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bartalena L, Baldeschi L, Boboridis K. et al; European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J 2016; 5 (01) 9-26
    CrossrefPubMedSuche in Google Scholar
  • 2 Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J 2018; 7 (04) 167-186
    CrossrefPubMedSuche in Google Scholar
  • 3 Bartalena L, Kahaly GJ, Baldeschi L. et al; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol 2021; 185 (04) G43-G67
    CrossrefPubMedSuche in Google Scholar
  • 4 Perros P, Baldeschi L, Boboridis K. et al; European Group of Graves' Orbitopathy. A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur J Endocrinol 2006; 155 (02) 207-211
    PubMedSuche in Google Scholar
  • 5 Brito JP, Nagy EV, Singh Ospina N. et al. A survey on the management of thyroid eye disease among American and European Thyroid Association members. Thyroid 2022; 32 (12) 1535-1546
    PubMedSuche in Google Scholar
  • 6 Ramos HE, Diehl LA, Camacho CP, Perros P, Graf H. Latin American Thyroid Society. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe. Clin Endocrinol (Oxf) 2008; 69 (06) 951-956
    PubMedSuche in Google Scholar
  • 7 Xu SH, Li XJ, Chen GF. et al. A questionnaire survey on the management of Graves' orbitopathy in China: a comparison with Europe and Latin-America. Chronic Dis Transl Med 2015; 1 (02) 117-123
    PubMedSuche in Google Scholar
  • 8 Chen J, Li C, Teng W. et al. A Chinese survey of clinical practice on the management of thyroid eye disease. Eur Thyroid J 2024; 13 (03) e230269
    PubMedSuche in Google Scholar
  • 9 Pradhan A, Ganguly A, Naik MN, Nair AG, Desai S, Rath S. Thyroid eye disease survey: an anonymous web-based survey in the Indian subcontinent. Indian J Ophthalmol 2020; 68 (08) 1609-1614
    PubMedSuche in Google Scholar
  • 10 Duntas LH, Benvenga S. Selenium: an element for life. Endocrine 2015; 48 (03) 756-775
    PubMedSuche in Google Scholar
  • 11 Contempre B, Dumont JE, Ngo B, Thilly CH, Diplock AT, Vanderpas J. Effect of selenium supplementation in hypothyroid subjects of an iodine and selenium deficient area: the possible danger of indiscriminate supplementation of iodine-deficient subjects with selenium. J Clin Endocrinol Metab 1991; 73 (01) 213-215
    PubMedSuche in Google Scholar
  • 12 Winther KH, Bonnema SJ, Cold F. et al. Does selenium supplementation affect thyroid function? Results from a randomized, controlled, double-blinded trial in a Danish population. Eur J Endocrinol 2015; 172 (06) 657-667
    PubMedSuche in Google Scholar
  • 13 Bülow Pedersen I, Knudsen N, Carlé A. et al. Serum selenium is low in newly diagnosed Graves' disease: a population-based study. Clin Endocrinol (Oxf) 2013; 79 (04) 584-590
    PubMedSuche in Google Scholar
  • 14 Kahaly GJ, Riedl M, König J, Diana T, Schomburg L. Double-blind, placebo-controlled, randomized trial of selenium in Graves hyperthyroidism. J Clin Endocrinol Metab 2017; 102 (11) 4333-4341
    PubMedSuche in Google Scholar
  • 15 Leo M, Bartalena L, Rotondo Dottore G. et al. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest 2017; 40 (03) 281-287
    PubMedSuche in Google Scholar
  • 16 Wang L, Wang B, Chen SR. et al. Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves' disease: a prospective pilot study. Horm Metab Res 2016; 48 (09) 559-564
    PubMedSuche in Google Scholar
  • 17 Calissendorff J, Mikulski E, Larsen EH, Möller M. A prospective investigation of Graves' disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms. Eur Thyroid J 2015; 4 (02) 93-98
    PubMedSuche in Google Scholar
  • 18 Negro R, Hegedüs L, Attanasio R, Papini E, Winther KH. A 2018 European Thyroid Association survey on the use of selenium supplementation in Graves' hyperthyroidism and Graves' orbitopathy. Eur Thyroid J 2019; 8 (01) 7-15
    CrossrefPubMedSuche in Google Scholar
  • 19 Beshyah SA, Sherif IH, Mustafa HE. et al. Patterns of clinical management of hypothyroidism in adults: an electronic survey of physicians from the Middle East and Africa. J Diabetes Endocr Pract 2021; 4: 75-82
    Thieme ConnectSuche in Google Scholar
  • 20 Beshyah SA, Ali KF. Management of adrenal insufficiency: a survey of perceptions and practices of physicians from the Middle East and North Africa. J Diabetes Endocr Pract 2021; 4: 125-130
    Thieme ConnectSuche in Google Scholar
  • 21 Beshyah SA, Khalil AB. Clinical practice patterns in managing thyroid nodules: the first survey from the Middle East and Africa. J Diabetes Endocr Pract 2021; 4: 167-174
    Thieme ConnectSuche in Google Scholar
  • 22 Beshyah SA, Bashir M, Hafidh K. et al. Impact of patient age on management of hypothyroidism: a survey of physicians from three developing regions. J Diabetes Endocr Pract 2024; 7 (03) 135-144
    Thieme ConnectSuche in Google Scholar
  • 23 Coulter I, Frewin S, Krassas GE, Perros P. Psychological implications of Graves' orbitopathy. Eur J Endocrinol 2007; 157 (02) 127-131
    PubMedSuche in Google Scholar
  • 24 Marcocci C, Altea MA, Leo M. Treatment options for Graves' orbitopathy. Expert Opin Pharmacother 2012; 13 (06) 795-806
    PubMedSuche in Google Scholar
  • 25 Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves' orbitopathy. J Clin Endocrinol Metab 2012; 97 (11) 3857-3865
    CrossrefPubMedSuche in Google Scholar
  • 26 Soeters MR, van Zeijl CJ, Boelen A. et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med 2011; 69 (07) 302-308
    PubMedSuche in Google Scholar
  • 27 Bartalena L, Marcocci C, Bogazzi F. et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338 (02) 73-78
    CrossrefPubMedSuche in Google Scholar
  • 28 Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR. Radioiodine therapy and Graves' ophthalmopathy. J Nucl Med 2008; 49 (06) 923-930
    PubMedSuche in Google Scholar
  • 29 Hegedüs L, Bonnema SJ, Smith TJ, Brix TH. Treating the thyroid in the presence of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012; 26 (03) 313-324
    PubMedSuche in Google Scholar
  • 30 Träisk F, Tallstedt L, Abraham-Nordling M. et al; Thyroid Study Group of TT 96. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94 (10) 3700-3707
    CrossrefPubMedSuche in Google Scholar
  • 31 Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008; 69 (06) 943-950
    PubMedSuche in Google Scholar
  • 32 Lai A, Sassi L, Compri E. et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010; 95 (03) 1333-1337
    CrossrefPubMedSuche in Google Scholar
  • 33 Wakelkamp IM, Tan H, Saeed P. et al. Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology 2004; 111 (08) 1557-1562
    CrossrefPubMedSuche in Google Scholar
  • 34 Shulhai AM, Rotondo R, Petraroli M. et al. The role of nutrition on thyroid function. Nutrients 2024; 16 (15) 2496
    PubMedSuche in Google Scholar
  • 35 Kipp AP, Strohm D, Brigelius-Flohé R. et al; German Nutrition Society (DGE). Revised reference values for selenium intake. J Trace Elem Med Biol 2015; 32: 195-199
    CrossrefPubMedSuche in Google Scholar